Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019033142) COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISM
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/033142 International Application No.: PCT/AU2018/000135
Publication Date: 21.02.2019 International Filing Date: 15.08.2018
Chapter 2 Demand Filed: 13.06.2019
IPC:
A61K 31/437 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/454 (2006.01) ,A61K 31/495 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Applicants:
BORODY, Thomas, Julius [AU/AU]; AU
Inventors:
BORODY, Thomas, Julius; AU
Agent:
SPRUSON & FERGUSON; GPO BOX 3898 Sydney, New South Wales 2001, AU
Priority Data:
62/545,98915.08.2017US
Title (EN) COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISM
(FR) COMPOSITIONS, DISPOSITIFS ET MÉTHODES DE TRAITEMENT DE L'AUTISME
Abstract:
(EN) The present invention relates to a method for treating, ameliorating, reversing and/or preventing autism or an autism spectrum disorder (ASD) via the administration of a formulation, a pharmaceutical preparation or a pharmaceutical composition comprising or consisting of: (a) a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIXT), an extended intestinal release (EIR) rifaximin, a rifamycin derivative, a rifampicin (or rifampin) (optionally RIFADIN), a rifabutin (optionally MYCOBUTIN), a rifapentine (optionally PRIFTIN), a rifalazil, a bicozamycin, or a mixture or combination thereof, or (b) a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIX) and at least one additional antimicrobial or antibiotic agent, wherein optionally the at least one additional antimicrobial or antibiotic agent comprises a vancomycin, a metronidazole (optionally FLAGYLTM, METROTM), a tinidazole (optionally FASIGYN, SIMPLOTAN, TINDAMAX) or a combination thereof
(FR) La présente invention concerne une méthode de traitement, d'amélioration, d'inversion et/ou de prévention de l'autisme ou d'un trouble du spectre de l'autisme (TSA) par l'administration d'une formulation, d'une préparation pharmaceutique ou d'une composition pharmaceutique comprenant ou consistant à : (a) un rifaximine (facultativement un XIFAXAN, XIFAXANTA ou NORMIXT), un rifaximine à libération intestinale prolongée (LIP), un dérivé de rifamycine, une rifampicine (ou rifampine) (facultativement RIFADIN), une rifabutine (facultativement MYCOBUTIN), une rifapentine (éventuellement PRIFTIN), un rifalazil, une bicozamycine, ou un mélange ou une combinaison de ceux-ci, ou (b) un rifaximine (facultativement un XIFAXAN, XIFAXANTA ou NORMIX) et au moins un agent antimicrobien ou antibiotique supplémentaire, l'agent ou les agents antimicrobiens ou antibiotiques supplémentaires comprenant une vancomycine, un métronidazole (éventuellement FLAGYLTM, METROTM), un tinidazole (éventuellement FASIGYN, SIMPLOTAN, TINDAMAX) ou une combinaison de ceux-ci
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)